Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Dec 2024 value amounting to $965,881.

  • Phathom Pharmaceuticals' Gains from Sales and Divestitures rose 51.43% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 51.43%. This contributed to the annual value of $965,881 for FY2024, which is 4.36% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Gains from Sales and Divestitures of $965,881 as of FY2024, which was down 4.36% from $1.0 million recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $1.0 million for FY2023, and its period low was $102,453 during FY2022.
  • In the last 3 years, Phathom Pharmaceuticals' Gains from Sales and Divestitures had a median value of $965,881 in 2024 and averaged $692,761.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 885.77% in 2023, then fell by 4.36% in 2024.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $102,453 in 2022, then surged by 885.77% to $1.0 million in 2023, then declined by 4.36% to $965,881 in 2024.